Department of Periodontics, SRM Dental College, Chennai, India.
Med Princ Pract. 2022;31(4):376-383. doi: 10.1159/000525560. Epub 2022 Jun 21.
The aim of this research was to determine and compare the clinical efficacy of leukocyte platelet-rich fibrin (L-PRF) and advanced platelet-rich fibrin (A-PRF) in combination with coronally advanced flap (CAF) in the treatment of gingival recession defects.
Systemically healthy subjects presenting with 30 Miller's class I or II gingival recession defects in maxillary anteriors and premolars, were treated with either CAF + L-PRF or CAF + A-PRF. Clinical parameters such as recession height (RH), width, probing pocket depth, clinical attachment level (CAL), keratinized tissue height (KTH), and width of attached gingiva (WAG) were measured at baseline, 3, and 6 months. Gingival biotype was evaluated at baseline and 6 months post-surgery. Mean root coverage percentage (MRC%) was evaluated at 3 and 6 months.
Statistically significant reduction in mean RH was observed from baseline (2.53 ± 0.74 mm, 2.63 ± 0.82 mm) to 6 months (0.87 ± 0.83 mm, 0.53 ± 0.91 mm) in CAF + L-PRF and CAF + A-PRF groups, respectively. The MRC% achieved at 6 months was 67.20 ± 32.81 in the CAF + L-PRF group and 81.66 ± 28.21 in the CAF + A-PRF group. Statistically significant gain in CAL, WAG, and KTH was observed in both therapeutic groups (p < 0.05). Intergroup analysis revealed no statistically significant differences among study parameters between groups at any time point (p > 0.05).
Based on the findings of this study, both L-PRF and A-PRF may be suggested as viable treatment options for the management of gingival recession in maxilla.
本研究旨在确定和比较白细胞富血小板纤维蛋白(L-PRF)和先进的富血小板纤维蛋白(A-PRF)与冠向推进瓣(CAF)联合治疗牙龈退缩缺陷的临床疗效。
系统地选择上颌前牙和前磨牙有 30 例 Miller Ⅰ类或Ⅱ类牙龈退缩缺陷的健康受试者,分别用 CAF+L-PRF 或 CAF+A-PRF 治疗。在基线、3 个月和 6 个月时测量临床参数,如退缩高度(RH)、宽度、探诊袋深度、临床附着水平(CAL)、角化组织高度(KTH)和附着龈宽度(WAG)。在基线和术后 6 个月时评估牙龈生物型。在 3 个月和 6 个月时评估平均根覆盖率百分比(MRC%)。
CAF+L-PRF 和 CAF+A-PRF 组从基线(2.53±0.74mm,2.63±0.82mm)到 6 个月(0.87±0.83mm,0.53±0.91mm)时,平均 RH 显著降低。CAF+L-PRF 组的 MRC%在 6 个月时为 67.20±32.81,CAF+A-PRF 组为 81.66±28.21。在两个治疗组中,CAL、WAG 和 KTH 均有显著增加(p<0.05)。组间分析显示,在任何时间点,组间研究参数均无统计学差异(p>0.05)。
根据本研究的结果,L-PRF 和 A-PRF 均可作为上颌牙龈退缩的可行治疗选择。